Grail (NASDAQ:GRAL – Get Free Report) announced its earnings results on Thursday. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55, Zacks reports. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million.
Grail Stock Down 14.7 %
Shares of GRAL opened at $40.73 on Friday. Grail has a 52-week low of $12.33 and a 52-week high of $63.99. The firm’s fifty day moving average is $26.32 and its two-hundred day moving average is $19.06.
Analyst Ratings Changes
Several equities research analysts have issued reports on GRAL shares. Wolfe Research started coverage on shares of Grail in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. Morgan Stanley started coverage on shares of Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price on the stock.
Grail Company Profile
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Further Reading
- Five stocks we like better than Grail
- Utilities Stocks Explained – How and Why to Invest in Utilities
- DuPont’s Electronics Spinoff: The Start of Something Big
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
